PMID- 37840948
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231020
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 10
DP  - 2023
TI  - Case report-CARMAT: the first experience with the Aeson bioprosthetic total 
      artificial heart as a bridge to transplantation in a case of post-infarction 
      ventricular septal rupture.
PG  - 1211365
LID - 10.3389/fcvm.2023.1211365 [doi]
LID - 1211365
AB  - BACKGROUND: Post-infarction ventricular septal defects remain one of the most 
      feared complications after myocardial infarction with high mortality rates. In 
      special cases, surgical or interventional treatment strategies are technically 
      not feasible and do not always lead to a good outcome. CASE PRESENTATION: A 
      58-year-old male patient in cardiogenic shock with a very large ventricular 
      septal (VSD) defect (4.9 cm x 5 cm) due to myocardial infarction was presented in 
      our department. Acute stabilization was achieved using peripheral venoarterial 
      extracorporeal membrane oxygenation (VA-ECMO) support. Neither surgical nor 
      interventional therapy was considered as a sufficient option due to the 
      unsuitable anatomy of the VSD and the patient was listed for heart 
      transplantation. After 2 weeks on ECMO, bleeding and infectious complications 
      occurred. Due to organ shortage, urgent implantation of the bioprosthetic total 
      artificial heart (TAH) Aeson device (CARMAT) remained the only useful strategy to 
      achieve a mid- or long-term bridge to transplantation. After successful 
      implantation and good recovery with the Aeson device, the patient was 
      transplanted 4 weeks after implantation. CONCLUSION: Post-infarction ventricular 
      septal defects are highly challenging and are commonly associated with a poor 
      prognosis. The implantation of the new Aeson TAH device is a promising 
      therapeutic option, allowing a safe and long-term bridging to heart 
      transplantation.
CI  - (c) 2023 Huenges, Panholzer, Cremer and Haneya.
FAU - Huenges, Katharina
AU  - Huenges K
AD  - Department of Cardiovascular Surgery, UKSH, Kiel, Germany.
FAU - Panholzer, Bernd
AU  - Panholzer B
AD  - Department of Cardiovascular Surgery, UKSH, Kiel, Germany.
FAU - Cremer, Jochen
AU  - Cremer J
AD  - Department of Cardiovascular Surgery, UKSH, Kiel, Germany.
FAU - Haneya, Assad
AU  - Haneya A
AD  - Department of Cardiovascular Surgery, UKSH, Kiel, Germany.
LA  - eng
PT  - Case Reports
DEP - 20230929
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC10570445
OTO - NOTNLM
OT  - VSD
OT  - heart failure
OT  - heart transplantation
OT  - myocardial infarction
OT  - total artificial heart
COIS- AH is a consultant for CARMAT. The remaining authors declare that the research 
      was conducted in the absence of any commercial or financial relationships that 
      could be construed as a potential conflict of interest.
EDAT- 2023/10/16 06:48
MHDA- 2023/10/16 06:49
PMCR- 2023/01/01
CRDT- 2023/10/16 04:25
PHST- 2023/04/24 00:00 [received]
PHST- 2023/08/24 00:00 [accepted]
PHST- 2023/10/16 06:49 [medline]
PHST- 2023/10/16 06:48 [pubmed]
PHST- 2023/10/16 04:25 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2023.1211365 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2023 Sep 29;10:1211365. doi: 10.3389/fcvm.2023.1211365. 
      eCollection 2023.